Biotia
BIOTIA-ID Urine Test Bundle (Qty. 3)
Test and Treat

BIOTIA-ID Urine Test Bundle (Qty. 3)

$550.00$1,950HSA/FSA

Keep at-home advanced testing on hand for when symptoms return or flare. Each test provides a comprehensive report for 44 key UTI-causing pathogens and 16 drug resistance markers, paired with virtual care from our telehealth partner.

What is included:

  • Three at-home test kits and laboratory analysis ($540)
  • Eligibility review and provider communications from Clinova.Solutions ($10)

Our credentials

Results you can trust

Live UTI Free 2026 Collaborator badge

Accountable to patients

Biotia collaborates with Live UTI Free, a leading patient advocacy group for people who experience UTIs.

CLIA-CLEP certification badge

CLIA-CLEP certified laboratory

Our New York laboratory holds CLIA and CLEP certifications, meeting the most rigorous regulatory standards.

Lock icon representing HIPAA compliance

HIPAA-compliant patient portal

Your information stays private and secure through our HIPAA-compliant patient portal.

Science icon representing demonstrated performance

Demonstrated performance

Validated in peer-reviewed studies with 97.2% sensitivity and 99.6% specificity across 1,470 urine specimens.

WHO IT'S FOR

For patients with unexplained or unresolved UTI symptoms

Our test and treat service was built for patients managing troublesome UTI symptoms who have yet to find answers through traditional care.

Take the quizHow it works
Process

From order to answers in just a few days

  1. Purchase the test
    1
  2. 2
    Complete your intake
  3. Activate your kit
    3
  4. 4
    Collect and send
  5. Receive your results
    5
  6. 6
    Get care
Sample Report

You deserve clarity

Our clinical reports are easy to understand for both patients and providers. See a sample report from the BIOTIA-ID Urine Test:

CLINICIAN-BACKED

Built in collaboration with leading clinicians

Dr. Angelish Kumar

Dr. Angelish Kumar

Clinical Advisor
"This cutting-edge technology allows for more precise and timely identification of atypical urogenital pathogens that often evade standard testing methods. By bridging this diagnostic gap, NGS technology may become an invaluable tool in tailoring targeted and effective treatment plans, ultimately elevating the standard of care for our most vulnerable patients suffering from complicated and recurrent UTI."
Dr. Michael H. Augenbraun
Clinical Collaborator
Dr. Michael H. Augenbraun
Reviews

Read our reviews